PURPOSE: CTL-associated antigen 4 (CTLA-4) can inhibit T-cell activation and helps maintain peripheral self-tolerance. Previously, we showed immune-related adverse events (IRAE) and objective, durable clinical responses in patients with metastatic melanoma treated with CTLA-4 blockade. We have now treated 139 patients in two trials and have sufficient follow-up to examine factors associated with clinical response. EXPERIMENTAL DESIGN: A total of 139 patients with metastatic melanoma were treated: 54 patients receivedipilimumab in conjunction with peptide vaccinations and 85 patients were treated with intra-patient dose escalation of ipilimumab and randomized to receive peptides in accordance with HLA-A*0201 status. RESULTS: Three patients achieved complete responses (CR; ongoing at 29+, 52+, and 53+ months); an additional 20 patients achieved partial responses (PR) for an overall objective response rate of 17%. The majority of patients (62%, 86 of 139) developed some form of IRAE, which was associated with a greater probability of objective antitumor response (P = 0.0004); all patients with CR had more severe IRAEs. Prior therapy with IFNalpha-2b was a negative prognostic factor, whereas prior high-dose interleukin-2 did not significantly affect the probability of response. There were no significant differences in the rate of clinical response or development of IRAEs between the two trials. The duration of tumor response was not affected by the use of high-dose steroids for abrogation of treatment-related toxicities (P = 0.23). There were no treatment-related deaths. CONCLUSION: In patients with metastatic melanoma, ipilimumab can induce durable objective clinical responses, which are related to the induction of IRAEs.
RCT Entities:
PURPOSE:CTL-associated antigen 4 (CTLA-4) can inhibit T-cell activation and helps maintain peripheral self-tolerance. Previously, we showed immune-related adverse events (IRAE) and objective, durable clinical responses in patients with metastatic melanoma treated with CTLA-4 blockade. We have now treated 139 patients in two trials and have sufficient follow-up to examine factors associated with clinical response. EXPERIMENTAL DESIGN: A total of 139 patients with metastatic melanoma were treated: 54 patients received ipilimumab in conjunction with peptide vaccinations and 85 patients were treated with intra-patient dose escalation of ipilimumab and randomized to receive peptides in accordance with HLA-A*0201 status. RESULTS: Three patients achieved complete responses (CR; ongoing at 29+, 52+, and 53+ months); an additional 20 patients achieved partial responses (PR) for an overall objective response rate of 17%. The majority of patients (62%, 86 of 139) developed some form of IRAE, which was associated with a greater probability of objective antitumor response (P = 0.0004); all patients with CR had more severe IRAEs. Prior therapy with IFNalpha-2b was a negative prognostic factor, whereas prior high-dose interleukin-2 did not significantly affect the probability of response. There were no significant differences in the rate of clinical response or development of IRAEs between the two trials. The duration of tumor response was not affected by the use of high-dose steroids for abrogation of treatment-related toxicities (P = 0.23). There were no treatment-related deaths. CONCLUSION: In patients with metastatic melanoma, ipilimumab can induce durable objective clinical responses, which are related to the induction of IRAEs.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Franz O Smith; Stephanie L Goff; Jacob A Klapper; Catherine Levy; Tamika Allen; Sharon A Mavroukakis; Steven A Rosenberg Journal: J Immunother Date: 2007-01 Impact factor: 4.456
Authors: Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg Journal: Proc Natl Acad Sci U S A Date: 2003-06-25 Impact factor: 12.779
Authors: Ralf Gutzmer; Andreas Wollenberg; Selma Ugurel; Bernhard Homey; Arnold Ganser; Alexander Kapp Journal: Dtsch Arztebl Int Date: 2012-02-24 Impact factor: 5.594
Authors: Laura C Cappelli; Mehmet T Dorak; Maria P Bettinotti; Clifton O Bingham; Ami A Shah Journal: Rheumatology (Oxford) Date: 2019-03-01 Impact factor: 7.580
Authors: Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok Journal: Proc Natl Acad Sci U S A Date: 2008-12-12 Impact factor: 11.205
Authors: Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos Journal: Gynecol Oncol Date: 2009-12-02 Impact factor: 5.482